Skip to main content
. 2017 Nov 30;7:16604. doi: 10.1038/s41598-017-16799-z

Figure 6.

Figure 6

Ectopic expression of CBFB confers resistance to the conventional anti-leukemia therapies. (a) IC50 values of Ara-C in CBFB-overexpressed MV4-11 cells. MV4-11 cells were transduced with lentivirus expressing CBFB (CBFB O/E) or control empty lentivirus. Cells were then treated simultaneously with 3 μM doxycycline and various concentrations of Ara-C. Forty-eight hours after treatment, IC50 values were calculated (n = 3). **P < 0.01, by two-tailed Student’s t-test. (b) IC50 values of Ara-C in Ara-C-naïve MV4-11 cells and Ara-C-resistant MV4-11 cells (MV4-11AR) (n = 3). (c) MV4-11AR cells highly express p53 and CBFB. Cell lysates prepared from parental MV4-11 cells and Ara-C-resistant MV4-11AR cells were analyzed by immunoblotting with the indicated antibodies. GAPDH was used as a loading control. (d) Ara-C treatment further augments p53 and CBFB expressions in MV4-11AR cells. MV4-11AR cells were treated with DMSO or with the increasing concentrations of Ara-C. Twenty-four hours after treatment, cell lysates were prepared and analyzed by immunoblotting with the indicated antibodies. GAPDH was used as a loading control. (e) A higher expression level of CBFB in AML cells obtained from the patients at the relapse phases relative to that at the primary phases (GSE17855 and GSE52891, n = 23). (f) Overall survival of AML patients with a higher or with a lower expression level of CBFB (GSE12417, high n = 17, low n = 62). P value by log-rank (Mantel-Cox) test. Data are mean ± SEM.